Assisted dying

Assisted dying

The Royal College of Pharmacy (RCPharm) takes a neutral stance on this topic; it is neither for nor against assisted dying.

Published: 15 October 2024

Updated: 3 November 2026

Assisting a person with a terminal condition to end their life at a time of their choosing (assisted dying), is an emotive and challenging subject.

Despite this neutral position, we maintain involvement in relevant legislative processes around this issue to ensure that the views of pharmacists are considered and that the content of any Bills brought in the future reflects pharmacy practice. We believe that any legislation must stipulate explicit legal protection for pharmacists. There must also be a conscience clause, so that pharmacists have the right to refuse to participate on any grounds.

Policy statement on assisted dying

Background and policy context

An increasing number of jurisdictions now permit some form of assisted dying, although legal models differ substantially.

Euthanasia and assisted dying are permitted in countries including the Netherlands, Belgium, Luxembourg, Spain and Canada.

Assisted suicide only is permitted in jurisdictions such as Switzerland, Germany and Austria.

Other regulated models have been introduced in Australia, parts of the United States and Colombia. Across all systems, eligibility criteria, safeguards and the extent of medical involvement vary, reflecting different legal and ethical approaches to assisted dying[1].

Over the last two years, (as the Royal Pharmaceutical Society) we undertook extensive advocacy work to represent the interests and perspectives of pharmacists on this issue; engaging with the UK Parliament in Westminster and the Scottish Parliament in Holyrood when the Terminally Ill Adults (End of Life) Bill and the Assisted Dying for Terminally Ill Adults (Scotland) Bill passed through the legislative process. Neither Bill became law[2][3].

In the event these laws are ever passed, every pharmacist would need to make a personal decision on whether or not they would wish to be involved in providing or supporting such a service.

The Royal College of Pharmacy is the professional body representing pharmacists in all sectors of the pharmacy profession. As such, there is a wide spectrum of members views to be considered and respected.

Policy objectives

This policy outlines our approach to the issues and challenges which the pharmacy profession would be presented with should assisted dying be legalised. It respects the views of individual pharmacists by providing suitable principles for those who wish to be involved, to work in partnership with the multidisciplinary team, whilst providing reassurance for those pharmacists opposed to assisted dying. 

The suggested principles outlined below demonstrate that the views, expressed by those for and against the concept, have been acknowledged and considered in developing our position. The principles take account of the issues that need to be addressed before a prescription to end a person’s life can be dispensed and seeks to ensure that patient access to the service is not compromised by inadequate signposting or service provision.

This document is a policy statement and is not intended as practice guidance. It is not meant to be definitive or overly prescriptive as the finer details of practice and procedure will still need to be developed depending on the exact nature of any new legislation. Fuller debate will also be required to accommodate patients’ needs in a variety of settings across all the home countries of Great Britain.

The document seeks to provide information and a clear direction on the requirements of the pharmacy profession to government policymakers, other professional bodies, health and social care colleagues, patients, the public and other key stakeholders. It has evolved with learning generated from engagement with this topic over recent years.

If legislation is passed, pharmacists will have a key role in developing suitable protocols and guidance for prescribers and other healthcare professionals. Policymakers must recognise and be aware that the role of pharmacists goes far beyond supply of the approved substance.

The RCPharm will work closely with policymakers and legislators to ensure that any legislation, and subsequent regulations, give careful consideration to the principles outlined in this policy. There is a professional duty to handle any conversations and interactions on this topic with compassion, sensitivity and respect. The UK Chief Pharmaceutical Officers have given advice to help pharmacists and pharmacy technicians who wish to take part in the assisted dying debate[4].

Proposals for changes in the law have sought to address solely the situation of a mentally competent person suffering from a terminal condition, whose quality of life has deteriorated to the extent that they now determine it to be intolerable and that they wish to end their life at a time of their choosing, rather than by the natural course of their disease. It is therefore in this context that we are specifically examining the issues around assisted dying from a pharmacy perspective and have not yet addressed the wider issue of either euthanasia or a broader patient group.

Definitions

Assisted dying – A term used to describe the process, initiated by a person voluntarily, who is dying and wishes to end their own life; which includes the assessment of eligibility amongst other requirements and prescription of an approved substance, which the person self-administers to bring about their own death. This term may also include Physician Assisted Dying or Physician Assisted Suicide, where the approved substance is administered by a physician rather than the person requesting assisted death. (Illegal in the UK at present)

Voluntary euthanasia – where one person makes a conscious decision to die and asks for help from another person to do so (illegal in the UK at present and there are no moves to change this position)[5].

Mental capacity – A person is considered mentally capable if they fit with the definitions of the Mental Capacity Act (England and Wales) 2005 and the Adults with Incapacity (Scotland) Act 2000[6][7].

Principles

Conscience clause – It is essential that a conscience clause is incorporated into any legislation. Pharmacists must have the legal protection to refuse to participate in any aspect of the process, on any grounds. No pharmacist should experience any form of detriment for exercising this right. Our view is that pharmacists should be able to ‘opt in’ by completing the necessary training, rather than ‘opting out’. It also avoids the need for anyone who does not wish to participate to signpost to another pharmacist as this could also pose an ethical dilemma.

Legal protection – There must be explicit protection in place in any legislation for pharmacists, pharmacy technicians and other health care professionals to be protected from prosecution when participating in the approved process for an assisted dying procedure. We would not anticipate any non-regulated pharmacy support staff to be involved in any of these procedures.

Criteria – All safeguards initially agreed in any prospective legislation need to be effective and rigorously applied. The criteria for eligibility should be steadfast and unable to be altered without proceeding through the primary legislative process.

Public or Private – If assisted dying were to become law, it should remain within the NHS, following the principles of equity of access and consistency and should not be shaped by commercial interests in the independent healthcare sector.

Mental capacity and eligibility – Mental capacity is fundamental to any decision about assisted dying. A person must be able to make an informed, voluntary choice, including understanding the nature and consequences of the decision and retaining the ability to change their mind at any stage. This requirement means that individuals who lack capacity, such as those with advanced dementia or Alzheimer’s disease, would be excluded, even though these are terminal conditions. This is a critical safeguard for any assisted dying process.

Palliative and End-of-Life Care – Requests for assisted dying should never be considered in isolation from the palliative and end-of-life care available. It cannot be assumed that such a request reflects a person’s true or informed preference; in some cases, it may arise from unmet needs, poor symptom control, or a lack of awareness of the support and treatment options available. Ensuring access to high-quality, person-centred palliative care is therefore essential, with a multidisciplinary and holistic approach that explores all physical, psychological, and social aspects of care.

Before any consideration of assisted dying, individuals should receive clear counselling and comprehensive information about all available alternatives. This includes detailed discussion of pain and symptom management, psychosocial support, and advances in palliative care that can significantly improve quality of life at the end of life. Patients must also be supported to understand the assisted dying process itself, including its implications, risks, and limitations, so that any decision is fully informed.

As experts in medicines, pharmacists are central to optimising symptom control, undertaking medication reviews, and addressing polypharmacy—particularly important in reducing side effects and improving comfort in the final stages of life. They contribute to ensuring safe, effective, and appropriate use of medicines, while also supporting patients and families with advice, reassurance, and education about treatment options.

Palliative care pharmacists have valuable expertise for developing protocols, but their involvement in assisted dying should not be assumed and may present conflicts of interest. Some, particularly in hospice settings, may choose not to participate due to concerns about patient and family perceptions.

All appropriate alternatives should be carefully considered and explored with a person requesting assisted dying. Evidence from services such as Dignitas suggests that access to information and supportive care can lead some individuals to pursue alternatives to assisted death[8]. This reinforces the importance of prioritising high-quality palliative care, with pharmacists as key contributors to delivering compassionate, safe, and holistic end-of-life support.

Established treatment pathways at the end of life should remain quite separate from a formal assisted dying procedure.

Assistance – A person must be able to self-administer the approved substance and be able to change their mind and halt the procedure at any point, to differentiate between assisted dying and euthanasia. A person’s physical state might deteriorate between making their decision to end their life and the date planned for the procedure.

Medical devices may be required to overcome physical limitations arising from an existing condition or the terminal illness. These needs should be clearly identified and addressed within the assisted dying care plan.

Assessment – Two doctors should carry out a full assessment of the patient, which carries the responsibility for ensuring that the patient fits the necessary eligibility criteria before an approved substance can be prescribed. All relevant medical records must be available to both assessors.

National approach – Despite the devolved nature of healthcare and legislation related to assisted dying, national guidance and protocols would be expected to be in place to ensure that best practice for the procedure is consistently applied across Great Britain. It would be necessary to look at all the available evidence and experience of other countries in developing protocols for pathways involving approved substances.

Similar protocols and procedures should be in place no matter in which setting the patient is being cared for. This would include hospital, hospice, care home, the patient’s own home and any other domiciliary setting. The protocol should also cover the issue of prescriptions, supply, documented use and return and disposal of any unused approved substances. In addition, we would expect there to be provisions for the manufacture, importation, distribution, storage, preparation and assembly of the approved substance. A robust audit trail is required.

Pharmacists must be included in any multidisciplinary working group to develop national guidance for all settings. The group membership should also include representation from the controlled drugs accountable officers’ network, particularly if controlled drugs are being considered for use. 

Registration with a GP in the country where the procedure is lawful and is to be carried out would also be required.

Patient care

Once the final request has been made by the patient and the necessary processes are complete as laid down within the law, arrangements would be made for the supply of the approved substance as laid out in the agreed protocols and procedures.

Close cooperation between pharmacy and medical colleagues would be required to facilitate all the necessary arrangements and ensure all documentation is in place before any supply is made. The timing and administration details require careful consideration to avoid patients requesting a procedure ahead of their own particular need to satisfy protocol and administrative requirements.

A person-centred approach is crucial for all aspects of assisted dying and people may change their mind. It is vital that the person can indicate their wishes until the final moments of their life.

Service arrangements should be sufficiently flexible to ensure equitable access across different geographical areas, recognising that the availability of healthcare professionals, including pharmacists who have opted to participate, may vary by locality.

A person’s wishes around confidentiality and the number of people party to the process need to be accommodated. Families and carers should not be subjected to any unnecessary pressure and stress at such an emotional time. They may or may not want to be involved in the practicalities of arranging a procedure. 

Patients should be able to talk to any healthcare professional about assisted dying and be advised or signposted accordingly. A mechanism to support the identification of healthcare professionals who have opted in to the service, such as a register, will be important to support patient choice, planning and access to clear, robust and reliable procedures. This should include contingency planning for occurrences where original personnel were to be unavailable for any reason.

Prescribing and dispensing

A pharmacist assumes a proportion of the responsibility for any approved substance or medicine supplied and therefore must be assured that all legal requirements are in place and that it is entirely appropriate for the patient. 

In addition to the usual practice of checking that the prescription fulfils the necessary legal requirements, pharmacists must have full access to the patient’s diagnosis and assisted dying documentation. As with any medicine supply, pharmacists hold a clear professional and legal accountability to ensure the dispensing activities for an approved substance comply with all legal requirements and regulatory standards. This will include verifying the validity of authorising documentation, including consent, ideally before the day of dispensing. Procedures must be in place to ensure that a pharmacist may raise a concern if they believe the patient has been coerced or has changed their mind. Close liaison between the doctor (or authorised person) and pharmacist will be necessary to ensure smooth and robust processes including safe storage, preparation, collection, return and safe disposal.

Accurate records will be required to ensure a robust audit trail and compliance with any regulations on record keeping and data analysis.

Consideration must be given to the appropriate timing of the request for the substance. Validity of prescriptions as well as the time taken for the pharmacist to review the necessary paperwork and the time between ordering and delivery, all must be taken into account when processes are produced. The exact details of this process will be dependent on any future model which may be chosen to facilitate assisted dying.

It is unclear whether any approved substances used for this procedure will have a marketing authorisation (MA) in the UK for human use or have an MA but will be used off-label rather than for the licensed indication. While this should not present any difficulties, the doctor, patient and pharmacist should be aware of this.

Training and education

In order to balance the needs of confidentiality and access to services, we advocate that pharmacists indicate their willingness to be involved by “opting in” to training and then be listed on a database alongside other healthcare professionals who would take part. Pharmacists who do not wish to be involved would not be listed and therefore would not be approached.

Pharmacists would need to be fully competent in the legal requirements of an assisted dying procedure and have knowledge of the necessary documentation, consent requirements and protocols. Joint training with other disciplines involved would be necessary to give a coordinated approach and common understanding of the process. 

It would be advantageous for any training to be holistic in nature and encompass some of the sensitivities pharmacists may encounter in practice. Training in advanced communication for end-of-life care, cultural attitudes towards death and dying and how to raise concerns if there is a suspicion of coercion will be important. Pharmacists may also require psychological support, and this might extend to the provision of peer support for colleagues or signposting to the Listening Friends service from Pharmacist Support if required. 

This training would also be available to pharmacy technicians. Training would always be optional, aligning with the conscience clause, but successful completion of the training would be mandatory before any involvement in an assisted dying procedure commences.

Organisations involved in the education and training of pharmacists and pharmacy technicians, namely Public Services Delivery Scotland Pharmacy, Centre for Pharmacy Postgraduate Education (CPPE) and Health Education and Improvement Wales (HEIW), would be key participants in supporting the development and delivery of educational packages whilst ensuring a coordinated national approach is adopted across GB.

Role of the pharmacist in any Assisted Death Procedure

Pharmacists will play a key role in supplying approved substances for assisted dying. However, subject to legislative models of care, this role could extend beyond supply to a more patient‑centred function, supporting the safe and effective use of the substance, including at the point of assisted death.

Other activities associated with assisted dying could include, but not be limited to:

  • The manufacture or preparation of the “approved substance”;
  • Dispensing, transportation and supply of the approved substance, including as part of the wider supply chain;
  • Advice on how to enable a person to self-administer the approved substance;
  • Developing protocols and guidance for prescribers;
  • Potential return and safe disposal of the approved substance.
Policy drafting process

In 2013, an expert working group was established with a cross-sector representation of pharmacists with expertise in many aspects of practice, including legal and ethical, palliative care, oncology, controlled drug accountable officers, hospices, education, primary care, community and hospital practice. Initial views from the working group were sought via a webinar and then disseminated to a wider reference group for feedback and comment. Members’ views were also sought through a virtual network discussion and coverage in the Pharmaceutical Journal.

In 2019, by invitation, Baroness Meacher, the Chair of Dignity in Dying, reviewed the terminology and language used within the policy.

In 2021, the policy was once again reviewed and the introduction updated to reflect the more recent activity around the subject. The document was then reviewed by the then Royal Pharmaceutical Society Boards in England, Scotland and Wales.

In 2024, a further review was completed following the introduction of the Assisted Dying for Terminally Ill Adults (Scotland) Bill and the decision in Jersey to proceed to law drafting for assisted dying for those with a terminal illness by the States Assembly. 

In 2026, this policy was reviewed again, reflecting the considerable activity at both Westminster and Holyrood on Assisted Dying legislation. The updated policy was reviewed and approved by the National Pharmacy Advisory Councils of the Royal College of Pharmacy.

We have attempted to be as inclusive as possible in the drafting process but recognise that this policy statement cannot fully encompass the breadth of opinions held, in good conscience, by all our membership. Feedback from our members is always encouraged, and the policy will be kept under review.

September 2026

References
  1. LegalClarity. What countries allow assisted suicide and euthanasia? [Internet]. 2026. Available from: ↩︎
  2. Royal College of Pharmacy. Statement: assisted dying for terminally ill adults (Scotland) bill [Internet]. 2026. Available from: ↩︎
  3. The Pharmaceutical Journal,. Burns C. House of Commons passes amendment allowing pharmacists to opt out of assisted dying process [Internet]. 2025. Available from: ↩︎
  4. UK Chief Pharmaceutical Officers. Assisted dying bill debate: advice to pharmacists and pharmacy technicians from the UK Chief Pharmaceutical Officers [Internet]. 2024. Available from: ↩︎
  5. NHS. Euthanasia and assisted suicide [Internet]. 2023. Available from: ↩︎
  6. NHS. Mental Capacity Act [Internet]. 2024. Available from: ↩︎
  7. Scottish Parliament. Adults with Incapacity (Scotland) Act 2000 [Internet]. 2000. Available from: ↩︎
  8. Dignitas (n.d.). So funkioniert Dignitas [Internet]. 2014. Available from: ↩︎